Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs AMINO ACIDS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLINIMIX E 2.75/5 is a combination of amino acids, electrolytes, and dextrose used for parenteral nutrition. The amino acids provide substrates for protein synthesis, dextrose supplies caloric energy, and electrolytes maintain acid-base and fluid balance. Calcium is included for bone health and neuromuscular function.
Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.
Parenteral nutrition for patients with or without electrolyte abnormalities who require intravenous feeding,Peripheral or central venous nutrition for prevention or treatment of negative nitrogen balance
Total parenteral nutrition (TPN) for patients unable to ingest or absorb adequate nutrients,Supplementation in metabolic disorders (e.g., urea cycle disorders, maple syrup urine disease),Treatment of negative nitrogen balance due to trauma, burns, or surgery
Intravenous administration. The dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 1 to 2 L per day of CLINIMIX E 2.75/5 with electrolytes in 5% dextrose with calcium, infused at a rate not exceeding 4 mg/kg/min of dextrose (or as tolerated).
1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.
Not applicable as a single entity; components have independent half-lives. Amino acids have plasma half-lives of minutes to hours depending on individual amino acid and metabolic state. Dextrose has an elimination half-life of 1.5-2.5 hours in normal glucose tolerance. Electrolytes are not described by half-life due to homeostatic regulation.
Variable; endogenous amino acids: 10–30 min for clearance from plasma; administered doses: distribution half-life ~5–10 min, terminal elimination half-life ~15–30 min, reflecting rapid metabolic utilization and renal reabsorption.
Amino acids are metabolized in the liver and peripheral tissues via transamination, deamination, and urea cycle. Dextrose is metabolized via glycolysis and the Krebs cycle. Electrolytes are distributed and excreted primarily by the kidneys. Calcium metabolism is regulated by the kidneys, bones, and gastrointestinal tract.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Specific pathways exist for each amino acid; excess nitrogen is converted to urea.
CLINIMIX E 2.75/5 is a parenteral nutrition solution; components are eliminated via normal metabolic pathways. Amino acids undergo deamination and oxidation, with nitrogen excreted renally as urea (80-90%). Glucose is metabolized to CO2 and water, excreted via lungs and kidneys. Electrolytes are excreted renally in proportion to intake and homeostatic regulation.
Renal: >95% as amino acids and metabolites, primarily reabsorbed; <5% unchanged. Fecal/biliary: negligible (<1%).
Amino acids are minimally protein bound (<10%); dextrose is not protein bound; electrolytes such as calcium and magnesium are partially bound to albumin (calcium ~50% bound, magnesium ~30% bound). Multivalent cations bind to various plasma proteins.
Minimal for most amino acids (<10%); albumin and globulins bind tryptophan and aromatic amino acids (~80–90% for tryptophan).
Not a single value. Amino acids distribute into total body water (~0.6 L/kg); dextrose distributes mainly into extracellular fluid (~0.2 L/kg) but is rapidly taken up by cells; electrolytes distribute according to their physiological compartments (e.g., sodium extracellular, potassium intracellular).
0.4–0.6 L/kg (total body water); reflects equilibration with intracellular and extracellular fluid compartments.
Intravenous administration yields 100% bioavailability. Not administered via other routes.
Oral: ~90–100% (active transport across intestinal mucosa); IV: 100%.
GFR > 50 m L/min: No adjustment needed. GFR 30-50 m L/min: Reduce volume by 50% or use a lower concentration of amino acids and electrolytes, monitor serum potassium, phosphate, and magnesium. GFR < 30 m L/min: Contraindicated or use extreme caution with dose reduction and close monitoring of electrolytes and fluid balance.
For GFR <30 m L/min: reduce dose to 0.5-1 g/kg/day; monitor serum amino acids and nitrogen balance.
Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce amino acid dose by 50% and monitor for hyperammonemia. Child-Pugh C: Use with caution; avoid if severe hepatic encephalopathy; may require reduction or use of specialized amino acid formulations.
Child-Pugh B or C: avoid standard formulations; use branched-chain amino acid (BCAA)-enriched solutions at 0.8-1.2 g/kg/day.
Weight-based dosing: Initiate at 0.5-1 g/kg/day of amino acids, increasing gradually to a target of 2-3 g/kg/day. Dextrose: start at 5-10 mg/kg/min, increase as tolerated up to 12-15 mg/kg/min. Electrolytes: adjust based on serum levels. Total volume: typically 100-150 m L/kg/day for infants, adjusted for clinical condition.
0.5-2 g/kg/day IV; titrate based on age, growth, and metabolic needs.
Elderly patients may have reduced renal and hepatic function. Start at lower end of dosing range (e.g., 1 L/day or less) and titrate slowly. Monitor fluid balance, electrolytes, and renal function closely. Avoid rapid infusion to prevent fluid overload.
Initiate at 0.8 g/kg/day IV, adjust based on renal function and nitrogen balance; monitor for fluid overload.
This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions which contain aluminum.
Patients receiving amino acid infusions should be monitored for metabolic acidosis, hyperammonemia, and renal function impairment. Solutions with electrolytes should not be used in patients with severe electrolyte imbalances.
Monitoring: serum electrolytes, blood glucose, fluid balance, liver function, renal function, and acid-base status,Risk of hyperglycemia, hyperosmolar state, and metabolic acidosis,Risk of aluminum toxicity, especially in renal impairment and premature infants,Do not administer unless solution is clear and container is undamaged,Use with caution in patients with heart failure, renal failure, or hepatic impairment
Use with caution in patients with renal impairment, hepatic failure, heart failure, or metabolic acidosis. Monitor serum electrolytes, blood urea nitrogen, and ammonia levels. Avoid rapid infusion to prevent hyperosmolarity and venous thrombosis.
Hypersensitivity to any component,Severe hyperglycemia (e.g., diabetic coma),Drug-induced lactic acidosis,Galactosemia (for dextrose-containing solutions),Severe electrolyte imbalances (unless corrected)
Hypersensitivity to any component, inborn errors of amino acid metabolism (e.g., phenylketonuria) without specific formula, severe hyperammonemia, anuria, or metabolic acidosis.
No direct food interactions, but parenteral nutrition may affect nutritional status. Enteral intake should be coordinated with the clinical team. Avoid concurrent administration of other IV solutions without compatibility check.
No significant food interactions; however, enteral nutrition should be managed to avoid excessive protein intake. Patients with phenylketonuria must avoid phenylalanine-containing amino acid solutions.
No known teratogenic risk; components (amino acids, dextrose, electrolytes) are physiological and essential for fetal development. No trimester-specific risks identified with standard use.
Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimester-specific human data; animal studies show no teratogenicity at standard doses.
Considered compatible with breastfeeding; components are normal constituents of human milk. M/P ratio not applicable as mixture of nutrients; no adverse effects reported.
Amino acids are normal constituents of breast milk; supplementation likely results in increased maternal levels but endogenous secretion maintains relatively constant milk levels. M/P ratio not established; generally considered compatible with breastfeeding at recommended doses.
No specific dose adjustments required; standard dosing per maternal weight and nutritional needs. Monitor for gestational changes in fluid and electrolyte requirements.
No specific dose adjustments required for enteral amino acids. For parenteral nutrition, consider increased requirements in third trimester (protein needs up to 1.5 g/kg/day). Adjust based on maternal weight gain, renal function, and metabolic monitoring.
CLINIMIX E 2.75/5 with electrolytes in dextrose 5% and calcium is a parenteral nutrition solution for IV use only. Monitor serum electrolytes, glucose, and renal function closely; do not administer simultaneously with blood products. Check for precipitate formation; use a dedicated line. Contains sulfite-free formulation for patients with sulfite sensitivity.
Amino acid infusions should be administered via central line if osmolarity > 900 m Osm/L to prevent thrombophlebitis. Monitor serum ammonia and BUN in patients with hepatic or renal impairment. Use with caution in patients with inborn errors of amino acid metabolism.
This medication is given through a vein (IV) and should be administered only by a healthcare professional.,Report any signs of infection at the IV site, such as redness, swelling, or pain.,Inform your healthcare provider of any history of allergies, especially to sulfites.,This solution provides complete nutrition, including amino acids, electrolytes, and dextrose. You may still eat or drink if permitted by your doctor.,Blood tests will be performed regularly to monitor your electrolyte levels, blood sugar, and kidney function.
This medication provides essential building blocks for protein synthesis.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Inform your doctor if you have liver or kidney disease.,Do not take other protein supplements unless directed by your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs AMINO ACIDS, answered by our medical review team.
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by CLINIMIX E 2.75/5 is a combination of amino acids, electrolytes, and dextrose used for parenteral nutrition. The amino acids provide substrates for protein synthesis, dextrose supplies caloric energy, and electrolytes maintain acid-base and fluid balance. Calcium is included for bone health and neuromuscular function.. AMINO ACIDS is a Parenteral Nutrition Solution that works by Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER and AMINO ACIDS depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous administration. The dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 1 to 2 L per day of CLINIMIX E 2.75/5 with electrolytes in 5% dextrose with calcium, infused at a rate not exceeding 4 mg/kg/min of dextrose (or as tolerated).. The standard adult dose of AMINO ACIDS is: 1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER and AMINO ACIDS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. No known teratogenic risk; components (amino acids, dextrose, electrolytes) are physiological and essential for fetal development. No trimester-specific risks identified with stand. AMINO ACIDS is classified as Category C. Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.